Disease · MONDO_0002280
Comparisons in its trials168
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 168
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Daprodustat vs Darbepoetin Alfa: Number of Participants With at Least One BP Exacerbation Event During Study | 939 of 1,919 | 1,012 of 1,884 | 3,803 | NCT02876835 | Trial comparisons |
| Daprodustat vs Darbepoetin Alfa: Number of Hgb Responders in the Hgb Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52) | 1,167 of 1,491 | 1,063 of 1,520 | 3,011 | NCT02876835 | Trial comparisons |
| Daprodustat vs rhEPO: deaths from any cause | 294 of 1,487 | 300 of 1,477 | 2,964 | NCT02879305 | Trial comparisons |
| Daprodustat vs rhEPO: serious adverse events | 773 of 1,482 | 748 of 1,474 | 2,956 | NCT02879305 | Trial comparisons |
| Daprodustat vs rhEPO: Number of Participants With at Least One BP Exacerbation Event During Study | 1,191 of 1,480 | 1,186 of 1,470 | 2,950 | NCT02879305 | Trial comparisons |
| Erythropoiesis Stimulating Agents vs Methoxy Polyethylene Glycol-Epoetin Beta: deaths from any cause | 557 of 1,409 | 558 of 1,409 | 2,818 | NCT00773513 | Trial comparisons |
| Erythropoiesis Stimulating Agents vs Methoxy Polyethylene Glycol-Epoetin Beta: serious adverse events | 1,123 of 1,409 | 1,097 of 1,409 | 2,818 | NCT00773513 | Trial comparisons |
| Daprodustat vs rhEPO: Number of Hgb Responders in the Hgb Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52) | 903 of 1,238 | 866 of 1,247 | 2,485 | NCT02879305 | Trial comparisons |
| Roxadustat vs Epoetin Alfa: deaths from any cause | 64 of 522 | 54 of 517 | 1,039 | NCT02052310 | Trial comparisons |
| Roxadustat vs Epoetin Alfa: serious adverse events | 234 of 522 | 218 of 517 | 1,039 | NCT02052310 | Trial comparisons |
| Roxadustat vs Placebo: deaths from any cause | 38 of 611 | 11 of 305 | 916 | NCT01750190 | Trial comparisons |
| Roxadustat vs Placebo: serious adverse events | 321 of 611 | 120 of 305 | 916 | NCT01750190 | Trial comparisons |
| Roxadustat vs Placebo: Number of Participants Who Received Blood/RBC Transfusion in the First 52 Weeks of Treatment | 34 of 608 | 47 of 305 | 913 | NCT01750190 | Trial comparisons |
| Roxadustat vs Placebo: Number (%) of Participants With Hb ≥10 g/dL Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy | 467 of 608 | 56 of 305 | 913 | NCT01750190 | Trial comparisons |
| Roxadustat vs Placebo: Ex-US Submission: Number (%) of Participants Who Achieved a Hb Response During the First 24-Weeks of Treatment Censoring for Rescue Therapy | 523 of 608 | 20 of 305 | 913 | NCT01750190 | Trial comparisons |
| Roxadustat vs Placebo: Number (%) of Participants Who Experienced Exacerbation of Hypertension | 140 of 608 | 48 of 305 | 913 | NCT01750190 | Trial comparisons |
| Hb-Based Titration Group vs Fixed Dose Group: deaths from any cause | 38 of 377 | 38 of 377 | 754 | NCT01652872 | Trial comparisons |
| Hb-Based Titration Group vs Fixed Dose Group: serious adverse events | 190 of 377 | 175 of 377 | 754 | NCT01652872 | Trial comparisons |
| Roxadustat vs Epoetin Alfa: deaths from any cause | 70 of 370 | 62 of 370 | 740 | NCT02273726 | Trial comparisons |
| Roxadustat vs Epoetin Alfa: serious adverse events | 242 of 370 | 248 of 370 | 740 | NCT02273726 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002280/comparisons